For now, Gilead has a pretty tight lock on the market, but competitors such as AbbVie (ABBV) are expected to debut treatments later this year. But Congress has no power over individual drug costs, so it's unlikely that all the carping will lead to anything, writes Nathan Sadeghi-Nejad in Forbes. The
